月度归档： 2026 年 7 月

世界农化网中文网报道：2026年6月30日，美国农业部动植物卫生检验局（APHIS）发布公告，决定解除对Soil Culture Solutions公司开发的CarriCea Carrizo柑橘砧木的管制。该砧木采用CRISPR/Cas9基因编辑技术开发，通过敲除Lls1、ACD2和CP等内源基因，增强其对柑橘黄龙病（Huanglongbing，又称citrus greening disease）的抗性。

Why it matters: The result weakens AstraZeneca’s attempt to expand eplontersen beyond hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), where the drug is already approved in more than 20 countries, including in the EU as Wainzua.

By Editor, Global AgInvesting MediaIn a major milestone for the Southern Hemisphere, Global AgInvesting (GAI) Australia, the world’s premier agricultural investment event, kicked off in Brisbane this June. The event marked the first time the prestigious global forum had been held outside the Northern Hemisphere, positioning Queensland at the forefront of international agribusiness and capital investment.

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …

Parkinson’s Disease as a progressive neurological disorder affecting body movement and coordination as neuron cells losing function in the substantia nigra section of the human brain as a degenerative illness.[wildpixel/Getty Images]

Why it matters: The move is another reminder of how difficult neurodegeneration remains for big pharma, even as Alzheimer’s and dementia research attracts renewed investment after the first disease-modifying amyloid drugs reached the market.

世界农化网中文网报道：2026年5月21日，安道麦辉丰（江苏）有限公司的36%咪鲜胺·噻霉酮悬浮剂产品获批扩作登记，新增登记作物和防治对象为油菜菌核病，推荐以30～50毫升/亩剂量，兑水量40～45公斤/亩，于油菜茎秆发病初期或油菜开花初期均匀喷雾施药1次，每季最多施药1次，安全间隔期21天。这是噻霉酮首次在我国油菜上登记，也是在我国油菜上登记的第3个咪鲜胺产品（不含登记证过期产品）。该产品原有的登记作物和防治对象为小麦赤霉病、水稻稻瘟病和柑橘树炭疽病。

Originally reported on Choose BrisbaneWith one of Australia’s most sophisticated supply chains, a rapidly growing infrastructure pipeline and an advanced manufacturing ecosystem rich in food and agritech expertise, Brisbane is scaling to meet global agriculture’s evolving demands.

By taking advantage of the microbe-targeting capabilities of bacteriophages (phages), researchers at McMaster university have devised a supportive therapy for Crohn’s disease that disarms a type of E. coli bacteria that drives inflammation in the gut without disrupting the broader gut microbiome. The team showed that the phage therapy also improved responses to low doses of a conventional corticosteroid in a mouse model of Crohn’s disease, suggesting treatment could both improve outcomes and lower the risk of side effects from standard therapies.